Compare Stocks → One trade. One ticker. One week. (From Wealthpin Pro) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AUTLNASDAQ:AVRONASDAQ:CLLSNASDAQ:GNFTNASDAQ:RCEL Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUTLAutolus Therapeutics$4.21-6.0%$5.80$1.61▼$7.45$1.12B1.91.52 million shs2.72 million shsAVROAVROBIO$1.19-1.7%$1.28$0.57▼$1.70$54.28M1.22272,822 shs348,448 shsCLLSCellectis$2.50-4.6%$2.64$0.96▼$3.77$145.61M3.1240,722 shs39,291 shsGNFTGenfit$3.45$3.59$2.89▼$4.75$171.68M1.084,408 shs3,539 shsRCELAVITA Medical$8.57-4.6%$15.08$8.46▼$21.70$220.34M1.33211,645 shs149,342 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUTLAutolus Therapeutics-6.03%-13.02%-33.49%-29.24%+143.35%AVROAVROBIO-1.65%-2.46%-2.46%-9.85%+34.46%CLLSCellectis-4.57%+1.63%-3.10%-10.39%+28.87%GNFTGenfit+0.44%-0.43%-5.36%-11.21%-7.89%RCELAVITA Medical-4.57%-8.64%-45.98%-48.74%-38.08%Biden replacement revealed? (Ad)A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.See his shocking evidence in this new reportMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAUTLAutolus Therapeutics2.6268 of 5 stars3.43.00.00.01.93.30.6AVROAVROBIO1.0438 of 5 stars3.03.00.00.00.01.70.6CLLSCellectis2.0614 of 5 stars3.52.00.00.00.62.51.3GNFTGenfit0.8098 of 5 stars3.53.00.00.00.60.00.0RCELAVITA Medical0.9404 of 5 stars3.42.00.00.01.10.00.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUTLAutolus Therapeutics2.80Moderate Buy$8.1693.82% UpsideAVROAVROBIO2.00Hold$2.0068.07% UpsideCLLSCellectis3.00Buy$8.50240.00% UpsideGNFTGenfit3.00Buy$11.00219.30% UpsideRCELAVITA Medical2.80Moderate Buy$27.80224.39% UpsideCurrent Analyst RatingsLatest AUTL, GNFT, AVRO, RCEL, and CLLS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/12/2024AUTLAutolus TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.004/11/2024RCELAVITA MedicalBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral4/9/2024AUTLAutolus TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$10.00 ➝ $11.004/5/2024GNFTGenfitHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.003/18/2024AUTLAutolus TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $10.003/14/2024AUTLAutolus TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.002/23/2024RCELAVITA MedicalPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$19.00 ➝ $21.002/23/2024RCELAVITA MedicalCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$22.00 ➝ $25.002/12/2024AUTLAutolus TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$8.00 ➝ $9.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUTLAutolus Therapeutics$1.70M658.57N/AN/A$0.64 per share6.58AVROAVROBION/AN/A$0.28 per share4.19$2.13 per shareN/ACLLSCellectis$16.50M8.42N/AN/A$2.76 per share0.91GNFTGenfit$41.31M4.16N/AN/A$1.48 per share2.33RCELAVITA Medical$50.14M4.39N/AN/A$1.92 per share4.46Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUTLAutolus Therapeutics-$208.38M-$1.19N/AN/AN/AN/A-105.75%-49.25%5/14/2024 (Confirmed)AVROAVROBIO$12.16M-$0.10N/AN/AN/AN/A-74.86%-65.11%5/9/2024 (Estimated)CLLSCellectis-$106.14M-$1.67N/AN/AN/A-346.65%-73.03%-32.22%5/2/2024 (Estimated)GNFTGenfit-$31.27MN/A0.00N/AN/AN/AN/AN/A7/4/2024 (Estimated)RCELAVITA Medical-$35.38M-$1.40N/AN/AN/A-70.56%-54.80%-38.08%5/13/2024 (Confirmed)Latest AUTL, GNFT, AVRO, RCEL, and CLLS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2024N/AAUTLAutolus Therapeutics-$0.10N/A+$0.10N/AN/AN/A 5/13/2024N/ARCELAVITA Medical-$0.26N/A+$0.26N/AN/AN/A 3/14/2024Q4 2023AUTLAutolus Therapeutics-$0.26-$0.44-$0.18-$0.44N/AN/A2/22/2024Q4 2023RCELAVITA Medical-$0.34-$0.28+$0.06-$0.28$14.10 million$14.20 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAUTLAutolus TherapeuticsN/AN/AN/AN/AN/AAVROAVROBION/AN/AN/AN/AN/ACLLSCellectisN/AN/AN/AN/AN/AGNFTGenfitN/AN/AN/AN/AN/ARCELAVITA MedicalN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUTLAutolus TherapeuticsN/A6.156.15AVROAVROBION/A15.7815.78CLLSCellectis0.572.202.20GNFTGenfit0.922.942.94RCELAVITA Medical0.817.887.46OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUTLAutolus Therapeutics72.83%AVROAVROBIO62.63%CLLSCellectis63.90%GNFTGenfit2.24%RCELAVITA Medical27.66%Insider OwnershipCompanyInsider OwnershipAUTLAutolus Therapeutics25.70%AVROAVROBIO9.20%CLLSCellectis16.41%GNFTGenfit4.20%RCELAVITA Medical2.05%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAUTLAutolus Therapeutics463265.93 million197.58 millionOptionableAVROAVROBIO1344.86 million40.73 millionOptionableCLLSCellectis23155.58 million46.46 millionOptionableGNFTGenfit15949.83 million47.74 millionNot OptionableRCELAVITA Medical20725.71 million25.18 millionOptionableAUTL, GNFT, AVRO, RCEL, and CLLS HeadlinesSourceHeadlineAVITA Medical Inc RCELmorningstar.com - April 19 at 10:46 AMAVITA Medical to Announce First Quarter 2024 Financial Resultsglobenewswire.com - April 15 at 5:05 PMShort Interest in AVITA Medical, Inc. (NASDAQ:RCEL) Grows By 22.9%marketbeat.com - April 15 at 1:33 PMAvita Medical Ltd (RCEL)investing.com - April 11 at 11:20 PMAnalysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE), Disc Medicine (IRON) and Avita Medical (RCEL)markets.businessinsider.com - April 11 at 1:19 PMBTIG downgrades Avita to neutral, cites lowered guidanceseekingalpha.com - April 11 at 1:19 PMAVITA Medical (NASDAQ:RCEL) Rating Lowered to Neutral at BTIG Researchmarketbeat.com - April 11 at 8:11 AMAVITA Medical Updates Expected First Quarter 2024 Revenueglobenewswire.com - April 10 at 5:11 PMRCEL Apr 2024 22.500 putfinance.yahoo.com - March 16 at 8:16 AMRCEL Oct 2024 17.500 putfinance.yahoo.com - March 16 at 8:16 AMAVITA Medical: Unconvincing Growth Amid Fierce Competition In The Burn Care Sectorseekingalpha.com - March 5 at 2:05 PMAVITA Medical Submits Response to FDA, Resuming Review Clock for RECELL GO PMA Supplementfinance.yahoo.com - February 29 at 4:15 PMAVITA Medical Submits Response to FDA, Resuming Review Clock for RECELL GO PMA Supplementglobenewswire.com - February 29 at 4:02 PMAVITA Medical to Present at TD Cowen 44th Annual Health Care Conferenceglobenewswire.com - February 29 at 9:00 AMAVITA Medical (RCEL) Price Target Increased by 6.80% to 26.69nasdaq.com - February 26 at 10:49 PMBRIEF-Seatrium Limited Says FY Revenue S$7.3 Blnsg.finance.yahoo.com - February 26 at 1:49 AMAvita Medical Poised for Growth: Strong Q4 Performance and Promising 2024 Outlook Reinforce Buy Ratingmarkets.businessinsider.com - February 23 at 5:44 PMAVITA Medical, Inc. (NASDAQ:RCEL) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - February 23 at 12:43 PMAVITA Medical to Host Investor Webinar Briefingglobenewswire.com - February 23 at 9:01 AMArdelyx Posts Q4 Loss, Joins MercadoLibre, Booking Holdings And Other Big Stocks Moving Lower In Friday's Pre-Market Sessionmsn.com - February 23 at 7:35 AMBuy Rating Affirmed for Avita Medical on Strong Financials and Expansive Growth Strategymarkets.businessinsider.com - February 23 at 2:34 AMAVITA Medical Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidanceglobenewswire.com - February 22 at 4:01 PMAVITA Medical Q4 2023 Earnings Previewmsn.com - February 21 at 2:21 PMRCEL Mar 2024 15.000 callfinance.yahoo.com - February 17 at 12:44 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains Imminent3 Companies Buying Back Stock Before New HighsApril 1, 2024 6:05 AMView 3 Companies Buying Back Stock Before New HighsUnited Parcel Service Is Setting Up for Another FallApril 24, 2024 6:15 AMView United Parcel Service Is Setting Up for Another FallAmazon Stock Insights & Analysis for 2024 April 22, 2024 7:13 AMView Amazon Stock Insights & Analysis for 2024 All Headlines Company DescriptionsAutolus TherapeuticsNASDAQ:AUTLAutolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It also focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.AVROBIONASDAQ:AVROAVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.CellectisNASDAQ:CLLSCellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.GenfitNASDAQ:GNFTGenfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.AVITA MedicalNASDAQ:RCELAVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.